What is Taconic?
Founded in 1952 and headquartered in Rensselaer, New York, Taconic Biosciences operates as a fully-licensed provider of sophisticated research models. The company serves as a critical partner for academic institutions, contract research organizations, and global pharmaceutical giants. Their service portfolio encompasses the entire lifecycle of research models, including custom generation, breeding, preconditioning, and global distribution. By maintaining rigorous quality standards and ethical compliance, Taconic has established itself as an indispensable node in the drug discovery and development value chain, facilitating breakthroughs in oncology, immunology, and metabolic disease research.
How much funding has Taconic raised?
Taconic has raised a total of $142M across 2 funding rounds:
Debt
$2M
Debt
$140M
Debt (2020): $2M with participation from PPP
Debt (2022): $140M led by MidCap Financial
Key Investors in Taconic
MidCap Financial
A middle-market-focused finance firm that provides flexible debt solutions and asset-based lending to support the growth and operational needs of established enterprises.
PPP
Public-Private Partnership
What's next for Taconic?
With the recent capital injection, Taconic is well-positioned to accelerate its strategic initiatives, particularly in the expansion of its high-throughput breeding facilities and the integration of advanced genomic technologies. The company is expected to focus on optimizing its supply chain logistics to meet the increasing demand for specialized research models in emerging therapeutic areas. Furthermore, the infusion of resources will likely support the enhancement of their digital infrastructure, enabling more seamless integration with client research workflows. As the life sciences industry continues to prioritize precision medicine, Taconic's ability to provide reliable, reproducible research models will remain a key driver of its competitive advantage and sustained growth in the coming fiscal periods.
See full Taconic company page
